Human cell adhesion protein AAMP-1 and uses thereof

Details Human cell adhesion protein AAMP-1 and uses thereof Human cell adhesion protein AAMP-1 and uses thereof

1993-06-25

2001-08-14

Nelson, Brett L. (Department: 1648)

Drug, bio-affecting and body treating compositions

Lymphokine

C530S350000, C536S027100

Reexamination Certificate

active

06274134

ABSTRACT:

BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates, in general, to AAMP-1, and to a peptide derived from the amino-terminal region of AAMP, P189. In particular, the present invention relates to a DNA segment encoding AAMP-1, P189 or fragments thereof; polypeptides encoded by the DNA segments; recombinant DNA molecules containing the DNA segments; cells containing the recombinant DNA molecule; a method of producing AAMP-1, P189 or fragments thereof; antibodies specific to AAMP-1; and a method of measuring the amount of AAMP-1 in a sample. The present invention further relates to methods of using AAMP, P189 or fragments thereof in promoting cell-cell or cell-substrate adhesion, wound healing in patients, prosthetic acceptance, concentrating heparin in tissues, and inhibiting metastases and invasion of malignant cells.
2. Background Information
The major histocompatibility complex class II proteins have recently been found to contain local homologies to the HIV-1 envelope protein (H. Golding et al.,
J. Exp. Med
. 167, 914 (1988); H. Golding et al.,
J. Clin. Invest
. 83, 1430 (1989); J. A. T. Young,
Nature
332, 215 (1988)). Such homologous regions may serve as targets for antibodies generated to HIV-1 proteins and thus compromise the immune system in AIDS. Golding et al. (
J. Exp. Med
. 167, 914 (1988)) have identified a common epitope located in the carboxy terminus of the HIV-1 gp4l-envelope protein and the amino terminal portion of the beta chain of all human HLA class II antigens. Although the epitope is small, 5 consecutive identities or similarities, they found that it is an effective example of “molecular mimicry” in that monoclonal antibodies raised against synthetic peptides from each protein react interchangeably with native HIV-1 envelope and MHC class II molecules. One third of HIV-1 positive individuals were shown to have serum antibodies directed against peptides derived from HIV-1 envelope protein, the homologous peptide from the MHC class II molecules, and native MHC class II molecules (H. Golding et al.
J. Exp. Med
. 167, 914 (1988)). Two other regions of the HLA class II beta chain and another immune related protein, interleukin-2, also show limited homology to HIV-1 (J. A. T. Young,
Nature
333:215 (1988); M. A. Vega et al.
Nature
345:26 (1990); W. E. Reiher III, et al.
Proc. Natl. Acad. Sci. USA
83:9188 (1986)). An important consideration in HIV-1 vaccine development is the potential existence of additional host cell surface proteins with homologies to HIV-1 that may cross-react with antibodies directed against its peptides.
Certain adhesive molecules are known to carry out cell-cell and cell-substrate interactions which play a central role in development, differentiation, immune functions, wound healing, malignant transformation, and tumor invasion metastasis. They provide structural patterns in tissue architecture, participate in transmembrane links between the cytoskeleton and the extracellular matrix, serve as directional guides for migrating cells, participate in signal transduction, provide strong adhesion that may inhibit cell motility, or alternatively, weak and/or reversible adhesion that provides traction in cell motility (Edelman, G. M. Ann. Rev. Cell Biol. 2:81-116 (1986); Edelman et al. Ann. Rev. Biochem. 60:155-90 (1991); Edelman, G. M., Dev. Dynamics 193:2-10 (1992); Behrens, J., et al., Sem Cell Biol. 3:169-78 (1992).
Members of the Immunoglobulin superfamily are known to exhibit diverse binding properties, and include many adhesive proteins. Modulation of such adhesive proteins has been shown to play stimulatory or inhibitory roles in normal and tumor cell migration via alterations in intercellular adhesion, cell to substratum adhesion, and adherence of tumor cells and leukocytes to endothelial cells (Buck, C. A., Sem. Cell Biol. 3:179-88 (1992); Shevach, E. M. Immunophysiology, The Role of Cells and Cytokines in Immunity and Inflamation (Oppenheim, J. J., and Shevach, E. M., eds.) pp.104-28, Oxford University Press, New York). Furthermore, heparin and hyaluronan, two glycosaminoglycans, are known to be involved with the binding mechanisms of some of these adhesive proteins, such as Neural Cell Adhesion Molecule (NCAM), and the Cluster Differentiation (CD) proteins, CD4 and CD44. See, e.g., Buck, C. A., Sem. Cell Biol. 3:179-88 (1992); Cole, G. J. et al., Nature 320:445-7 (1986); Cole, G. J. et al., Neuron 2:1157-65 (1989); Reyes et al., Cell Regul. 1:567-76 (1990); Arufo et al., Cell 61:1303-13 (1990); Miyake et al., J. Exp. Med. 172:69-75 (1990); and Lederman, S. et al., J. Immunol. 143:1149-54 (1989).
The use of heparin binding proteins and peptides to promote heparin binding to synthetic substrates, cell adhesion to culture substrata, implant acceptance, and wound healing, as well as their use in inhibiting tumor metastasis and malignant cell invasion, has been previously described. (U.S. Pat. No. 5,081,031 to Furcht et al., U.S. Pat. No. 5,152,784, to Tsilibary et al., U.S. Pat. No. 5,120,828, to Charonis).
SUMMARY OF THE INVENTION
The present invention relates to the protein AAMP-1 which has immunoglobulin (Ig) type domains that contain strong local homologies to conserved regions of the HIV-1 envelope and nef proteins. The invention further relates to polypeptide, P189, derived from the amino terminal region of AAMP. Both P189 and AAMP are capable of promoting cell aggregation, and heparin binding.
It is a general object of this invention to provide AAMP-1 or a fragment thereof.
It is a specific object of this invention to provide a DNA segment which encodes AAMP-1, or a fragment thereof.
It is a further object of the invention to provide a polypeptide corresponding to a AAMP-1 gene, or a fragment thereof.
It is another object of the invention to provide a recombinant DNA molecule comprising a vector and a DNA segment encoding a AAMP-1 gene, or a segment thereof.
It is a further object of the invention to provide a cell that contains the above-described recombinant molecule.
It is another object of the invention to provide a method of producing the polypeptide, or its fragments, encoded for by the AAMP-1 gene, or segments thereof.
It is a further object of the invention to provide antibodies having binding affinity for AAMP-1, or a unique fragment thereof.
It is a further object of the invention to provide a method of measuring the amount of AAMP-1, or its fragments, in a sample.
It is another object of the invention to provide a therapeutic modality comprising the above-described polypeptides in an amount effective to elicit protective antibodies, block harmful auto-antibodies, or compete for HIV binding to body cells in a patient to the AIDS virus and a pharmaceutically acceptable diluent, carrier, or excipient.
It is also an object of the invention to provide P189 peptide or a fragment thereof.
It is a further object of the invention to provide a DNA segment encoding the P189 peptide or a fragment thereof.
It is an additional object of this invention to provide a method for mediating cell-cell and cell-substrate adhesion comprising the use of AAMP or a related heparin binding peptide.
It is also an object of this invention to provide methods for promoting cellular attachment to culture substrata, prosthetic acceptance, and wound healing, and for inhibiting metastasis and invasion by malignant cells, wherein said methods comprise the use of AAMP or its related heparin binding peptides.
Further objects and advantages of the present invention will be clear from the description that follows.


REFERENCES:
patent: 4839464 (1989-06-01), McCarthy
patent: 4870160 (1989-09-01), Charonis
patent: 5081031 (1992-01-01), Tsilibary
patent: 5110906 (1992-05-01), Maddon
patent: 5120828 (1992-06-01), Charonis
patent: 5126433 (1992-06-01), Maddon
patent: 5152784 (1992-10-01), Tsilibary
patent: 01493 (1989-02-01), None
patent: 01942 (1989-03-01), None
patent: 13566 (1990-11-01), None
patent: 09113 (1991-06-01), None
patent: 09054 (1991-06-01), None
patent: 12739 (1992-08-01), None
patent: 15202 (1993-08-01), No

Affiliated with

Also associated with

Rating

Human cell adhesion protein AAMP-1 and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Human cell adhesion protein AAMP-1 and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human cell adhesion protein AAMP-1 and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2443203